BRPI0415113A - compostos de lactama condensados - Google Patents

compostos de lactama condensados

Info

Publication number
BRPI0415113A
BRPI0415113A BRPI0415113-5A BRPI0415113A BRPI0415113A BR PI0415113 A BRPI0415113 A BR PI0415113A BR PI0415113 A BRPI0415113 A BR PI0415113A BR PI0415113 A BRPI0415113 A BR PI0415113A
Authority
BR
Brazil
Prior art keywords
group
compound
disease
compounds
substituted
Prior art date
Application number
BRPI0415113-5A
Other languages
English (en)
Inventor
Kazuo Ando
Masako Hirota
Makoto Kawai
Hirohisa Shimokawa
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of BRPI0415113A publication Critical patent/BRPI0415113A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Addiction (AREA)
  • Psychology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

"COMPOSTOS DE LACTAMA CONDENSADOS". Esta invenção proporciona um composto da fórmula (I): em que R¬ 1¬ representa um grupo arila tendo de 6 a 10 átomos de carbono em anel etc.; R¬ 2¬ representa um átomo de hidrogênio, etc., n representa 0, 1 ou 2; o referido grupo heteroarila é não substituído ou substituído e o referida arila é substituída por pelo menos um substituinte selecionado do grupo constituída por substituintes <244>; os referidos substituintes <244> são selecionados do grupo constituído por átomos de halogênio, grupos alquila tendo desde 1 a 6 átomos de carbono, etc.; ou um éster farmaceuticamente aceitável de tal composto, ou um seu sal farmaceuticamente aceitável. Estes compostos são úteis para o tratamento de condições de doença causadas por sobreativa do receptor NR2B de NMDA tal como dor, acidente vascular cerebral, lesão cerebral traumática, mal de Parkinson, mal de Alzheimer, depressão, ansiedade, enxaqueca ou semelhantes, num mamífero, especialmente seres humanos. Esta invenção também proporciona uma composição farmacêutica compreendendo o composto acima.
BRPI0415113-5A 2003-10-08 2004-09-27 compostos de lactama condensados BRPI0415113A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US50967003P 2003-10-08 2003-10-08
PCT/IB2004/003125 WO2005035523A1 (en) 2003-10-08 2004-09-27 Fused lactam compounds

Publications (1)

Publication Number Publication Date
BRPI0415113A true BRPI0415113A (pt) 2006-11-28

Family

ID=34435007

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0415113-5A BRPI0415113A (pt) 2003-10-08 2004-09-27 compostos de lactama condensados

Country Status (6)

Country Link
EP (1) EP1673367A1 (pt)
JP (1) JP2007508288A (pt)
BR (1) BRPI0415113A (pt)
CA (1) CA2541162A1 (pt)
MX (1) MXPA06003748A (pt)
WO (1) WO2005035523A1 (pt)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1736474A4 (en) * 2004-04-07 2010-04-21 Kyowa Hakko Kirin Co Ltd piperidine
CA2805371C (en) 2010-07-30 2017-10-31 Toray Industries, Inc. Therapeutic agent or prophylactic agent for neuropathic pain
KR20140146217A (ko) 2012-04-20 2014-12-24 유씨비 파마, 에스.에이. 파킨슨병을 치료하는 방법
US20140206667A1 (en) 2012-11-14 2014-07-24 Michela Gallagher Methods and compositions for treating schizophrenia
JP6433482B2 (ja) 2013-03-15 2018-12-05 エージンバイオ， インコーポレイテッド 認知機能を改善するための方法および組成物
WO2014144663A1 (en) 2013-03-15 2014-09-18 The Johns Hopkins University Methods and compositions for improving cognitive function
US9187506B2 (en) * 2014-01-09 2015-11-17 Bristol-Myers Squibb Company (R)-3-((3S,4S)-3-fluoro-4-(4-hydroxyphenyl)piperidin-1-yl)-1-(4-methylbenzyl)pyrrolidin-2-one and its prodrugs for the treatment of psychiatric disorders
US9221796B2 (en) 2014-01-09 2015-12-29 Bristol-Myers Squibb Company Selective NR2B antagonists
WO2016191288A1 (en) 2015-05-22 2016-12-01 Agenebio, Inc. Extended release pharmaceutical compositions of levetiracetam
BR112018007181A2 (pt) 2015-10-14 2018-10-16 Bristol-Myers Squibb Company antagonistas de nr2b seletivos

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991017156A1 (en) * 1990-05-10 1991-11-14 Pfizer Inc Neuroprotective indolone and related derivatives
EP0594729A1 (en) * 1991-07-17 1994-05-04 Pfizer Inc. 2-(4-hydroxypiperidino)-1-alkanol derivatives as antiischemic agents
FR2688504B1 (fr) * 1992-03-13 1995-05-05 Synthelabo Derives de 2-(piperidin-1-yl)ethanol, leur preparation et leur application en therapeutique.
DK0666854T3 (da) * 1992-10-30 1997-04-28 Pfizer Neurobeskyttende 3,4-dihydro-2(1H)-quinolon forbindelser
US5498610A (en) * 1992-11-06 1996-03-12 Pfizer Inc. Neuroprotective indolone and related derivatives
US6713490B2 (en) * 2002-04-26 2004-03-30 Pfizer, Inc. 3,4-dihydroquinolin-2(1H)-one compounds as NR2B receptor antagonists

Also Published As

Publication number Publication date
CA2541162A1 (en) 2005-04-21
WO2005035523A1 (en) 2005-04-21
JP2007508288A (ja) 2007-04-05
MXPA06003748A (es) 2006-06-14
EP1673367A1 (en) 2006-06-28

Similar Documents

Publication Publication Date Title
BRPI0510666A (pt) compostos de amida de arila ou heteroarila de metila substituìda, composições farmacêuticas compreendendo os mesmos, uso e combinação
BRPI0409241A (pt) compostos bicìclicos como antagonistas do receptor de nr2b, composições farmacêuticas compreendendo os mesmos e seu uso
BRPI0414514A (pt) uso de um composto, composto, e, composições farmacêuticas
MA28515B1 (fr) Inhibiteurs de gsk-3
EA200301216A1 (ru) Замещенные хинуклидинами мультициклические гетероарилы для лечения заболевания
BRPI0408591A (pt) derivados de 6,7,8,9-tetrahidropirimido[1,2-a] pirimidin-4-ona 8-substituìda
AR036596A1 (es) Derivados de 4,5-dihidro-1h-pirazol que tienen actividad antagonista de cb1
BRPI0414130B8 (pt) compostos de fenilamida ou piridilamida, seu uso e composições farmacêuticas que os compreendem.
BRPI0615111B8 (pt) composto, composição farmacêutica, e, uso do composto
BRPI0418082B8 (pt) derivados de tiazol úteis como antagonistas de receptor de adenosina a2a
BRPI0610030B8 (pt) Composto, composição farmacêutica, e, uso de um composto
BRPI0409042A (pt) derivados de 4-pirimidona-2,3,6-tri-substituìdos
BR0014137A (pt) Composto, método para inibir a aurora 2 quinase em um animal de sangue quente, uso de um composto, e, composição farmacêutica
HUP0401889A2 (hu) 1,8-Naftiridin-származékok mint antidiabetikumok és ezeket tartalmazó gyógyszerkészítmények
BR0306208A (pt) Compostos de dibenzilamina e seu uso farmacêutico
BRPI0509377A (pt) compostos de ácido alfa arila ou heteroaril metil beta piperidino propanóico como antagonistas do receptor orl1
EA200200716A1 (ru) Арилконденсированные азаполициклические соединения
BRPI0512916A (pt) derivado de tienopirazol tendo atividade inibidora de pde 7
BRPI0415113A (pt) compostos de lactama condensados
BRPI0408605A (pt) derivados de 8-perfluoralquil-6,7,8,9-tetrahidropirimido[1,2-a]piri midin-4-ona substituìdos
BR0212896A (pt) Derivados de 2-piridinil-6,7,8,9-tetrahidropirimido[1,2-a]pirimidin-4- ona e 7-piridinil-2,3dihidroimidazo[1,2-a] pirimidin-5(1h)ona substituìdos
AR040928A1 (es) Compuestos de acidos sulfona-hidroxamicos aromaticos, composiciones farmaceuticas y su uso en la preparacion de medicamentos utiles como inhibidores de proteasas
BRPI0517740A (pt) compostos n-sulfonilaminobenzil-2fenóxi acetamida substituìda
BRPI0415109A (pt) compostos de 1-[2-(4-hidroxifenil)-2-hidroxietil]-piperidin-4-ol como antagonistas de receptor de nmda
AR026470A1 (es) Un compuesto de pirazolpirazina, proceso para prepararlo, las composiciones farmaceuticas que lo contienen y su preparacion, y el uso de dichos compuestospara la preparacion de medicamentos.

Legal Events

Date Code Title Description
B08F Application fees: dismissal - article 86 of industrial property law

Free format text: REFERENTE AS 5A, 6A E 7A ANUIDADES.

B08K Lapse as no evidence of payment of the annual fee has been furnished to inpi (acc. art. 87)

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2158 DE 15/05/2012.